Clinical and economic consequences of mucositis induced by chemotherapy and/or radiation therapy

Journal of Supportive Oncology

Volumn 5, Issue 9 SUPPL. 4, 2007, Pages 13-21

  Murphy, Barbara A ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; METHOTREXATE; MORPHINE; PALIFERMIN;

ANEMIA; ANOREXIA; CACHEXIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL FEATURE; COGNITIVE DEFECT; COST OF ILLNESS; DEPRESSION; DIETARY INTAKE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; ENVIRONMENTAL FACTOR; FATIGUE; FRACTIONATION; GENETIC POLYMORPHISM; GRAFT VERSUS HOST REACTION; HEAD AND NECK CANCER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITALIZATION COST; HUMAN; MOUTH FLORA; MOUTH INFECTION; MOUTH ULCER; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PHYSICAL EXAMINATION; QUALITY OF LIFE; RADIATION DOSE; RADIATION INJURY; REVIEW; RISK FACTOR; SCORING SYSTEM; SIDE EFFECT; STOMATITIS; TASTE DISORDER; THERAPY DELAY; TREATMENT FAILURE; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS; HEAD AND NECK NEOPLASMS; HEALTH CARE COSTS; HUMANS; PROGNOSIS; RADIOTHERAPY; STOMATITIS; WEIGHT LOSS;

EID: 35748932952     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Sonis S. The pathobiology of mucositis. Nat Rev Cancer 2004;4:277-284.[15057287]
2. Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004;351:2590-2598. [15602019]
3. Sonis ST, Eilers JP, Epstein JB, et al. Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. Cancer 1999;85:2103-2113. [10326686]
4. Epstein JB, Beaumont JL, Gwede CK, et al. Longitudinal evaluation of the oral mucositis weekly questionnaire-head and neck cancer, a patient-reported outcomes questionnaire. Cancer 2007;109:1914-1922. [17377917]
5. Scully C, Epstein J, Sonis S. Oral mucositis: a challenging complication of radiotherapy, chemotherapy, and radiochemotherapy: part 1, pathogenesis and prophylaxis of mucositis. Head Neck 2003;25:1057-1070. [14648865]
6. Scully C, Sonis S, Diz PD. Oral mucositis. Oral Dis 2006;12:229-241. [16700732]
7. Pico JL, Avila-Garavito A, Naccache P. Mucositis: its occurence, consequences, and treatment in the oncology setting. Oncologist 1998;3:446-451. [10388137]
8. Elting LS, Cooksley C, Chambers M, Cantor SB, Manzullo E, Rubenstein EB. The burdens of cancer therapy: clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 2003;98:1531-1539. [14508842]
9. Donnelly JP, Muus P, Schattenberg A, De Witte T, Horrevorts A, DePauw BE. A scheme for daily monitoring of oral mucositis in allogeneic BMT recipients. Bone Marrow Transplant 1992;9:409-413. [1628123]
10. Blijlevens NM, Donnelly JP, De Pauw BE. Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview. Bone Marrow Transplant 2000;25:1269-1278.[10871732]
11. Sonis ST, Oster G, Fuchs H, et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 2001;19:2201-2205. [11304772]
12. Bellm LA, Epstein JB, Rose-Ped A, Martin P, Fuchs HJ. Patient reports of complications of bone marrow transplantation. Support Care Cancer 2000;8:33-39. [10650895]
13. Anderson KO, Giralt SA, Mendoza TR, et al. Symptom burden in patients undergoing autologous stem-cell transplantation. Bone Marrow Transplant 2007;39:759-766. [17438588]
14. Wardley AM, Jayson GC, Swindell R, et al. Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue. Br J Haematol 2000;110:292-299. [10971384]
15. Cutler C, Li S, Kim HT, et al. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens. Biol Blood Marrow Transplant 2005;11:383-388. [15846292]
16. Albertioni F, Rask C, Schroeder H, Peterson C. Monitoring of methotrexate and 7-hydroxymethotrexate in saliva from children with acute lymphoblastic leukemia receiving high-dose consolidation treatment: relation to oral mucositis. Anticancer Drugs 1997;8:119-124. [9073308]
17. Robien K, Schubert MM, Bruemmer B, Lloid ME, Potter JD, Ulrich CM. Predictors of oral mucositis in patients receiving hematopoietic cell transplants for chronic myelogenous leukemia. J Clin Oncol 2004;22:1268-1275. [15051775]
18. Woo SB, Sonis ST, Monopoli MM, Sonis AL. A longitudinal study of oral mucositis in bone marrow transplant patients. Cancer 1993;72:1612-1617. [8348492]
19. Woo B, Dibble SL, Piper BF, Keating SIB, Weiss MC. Differences in fatigue by treatment methods in women with breast cancer. Oncol Nurs Forum 1998;25:915-920. [9644708]
20. Sonis ST, Elting LS, Keefe D, et al. Perspectives on cancer therapy-induced mucosal injury pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 2004;100:1995-2025. [15108222]
21. Trotti A, Bellm LA, Epstein JB, et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy:a systematic literature review Radiother Oncol 2003;66:253-262. [12742264]
22. Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinoma: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000;48:7-16. [10924966]
23. Wong PC, Dodd MJ, Miaskowski C, et al. Mucositis pain induced by radiation therapy: prevalence, severity, and use of self-care behaviors. J Pain Symptom Manage 2006,32:27-37. [16824982]
24. Duncan GG, Epstein JB, Tu D, et al; National Cancer Institute of Canada Clinical Trials Group. Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis. Head Neck 2005;27:421-428. [15782422]
25. Keefe DM, Garden A, Barasch A, et al. Oral mucositis is associated with increased resource use among patients receiving treatment for cancers of the head and neck. J Clin Oncol 2007;25(20S):6070.
26. Murphy BA, Gilbert J, Ridner SH. Systemic and global toxicities of head and neck treatment. Expert Rev AnticancerTher 2007;7:1043-1053. [17627463]
27. Clayton F, Tessnow KA, Fang JC, Holden JA, Moore JG. Circadian variation of topoisomerase II-alpha in human rectal crypt epithelium: implications for reduction of toxicity of chemotherapy. Mod Pathol 2002;15:1191-1196. [12429798]
28. Bjarnason GA, MacKenzie R, Hodson I, et al. A randomized prospective phase-III study comparing the acute oral mucositis of morning vs. afternoon radiotherapy (RT) in patients (pts) with squamous cell carcinoma ofthe head and neck (SCCHN): NCIC-CTG HN.3. J Clin Oncol 2005;23(16S):5500.
29. Chansky K, Benedetti J, Macdonald JS. Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma. Cancer 2005;103:1165-1171. [15693031]
30. McCollum AD, Catalano PJ, Haller DG, et al. Outcomes and toxicity in African-American and Caucasian patients in a randomized adjuvant trial for colon cancer. J Natl Cancer Inst 2002;94:1160-1167. [12165641]
31. Barasch A, Peterson DE. Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions. Oral Oncol 2003;39:91-100. [12509961]
32. Stokman MA, Spijkervet FK, Burlage FR, et al. Oral mucositis and selective elimination of oral flora in head and neck cancer patients receiving radiotherapy: a double-blind randomised clinical trial. Br J Cancer 2003;88:1012-1016. [12671696]
33. Wijers OB, Levendag PC, Harms ER, et al. Mucositis reduction by selective elimination of oral flora in irradiated cancers of the head and neck: a placebo controlled double-blind randomized study. Int J Radiat Oncol Biol Phys 2001;50:343-352. [11380220]
34. Sonis ST, Peterson RL, Edwards LJ,. Defining mechanisms of action of interleukin-11 on progression of radiation-induced mucositis in hamsters. Oral Oncol 2000;36:373-381. [10899677]
35. Gibson RJ, Keefe DM, Thompson FM, Clarke JM, Goland GJ, Cummins AG. Effect of interleukin-11 on ameliorating intestinal damage after methotrexate treatment of breast cancer in rats. Dig Dis Sci 2002;47:2751-2757. [12498296]
36. Hall PD, Benko H, Hogan KR, Stuart RK. The influence of human serum tissue necrosis factor-alpha and interleukin-6 on concentrations on non-hematologic toxicity and hematologic recovery in patients with acute myelogenous leukemia. Exp Hematol 1995;23:1256-1260. [7589279]
37. Lalla RV, Schubert MM, Bensadoun RI, Keefe D. Anti-inflammatory agents in the management of alimentary mucositis. Support Care Cancer 2006;14:558-565. [16565821]
38. Ulrich CM, Yasui Y, Storb R, et al. Pharmacogenetics of methotrexate: toxicity among marrow transplant patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood 2001;98:231-234. [11418485]
39. Stiff PJ, Emmanouilides C, Bensinger WI, et al. Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. J Clin Oncol 2006;24:5186-5193. [16391299]
40. Cella D, Pulliam J, Fuchs H, et al. Evaluation of pain associated with oral mucositis during the acute period after administration of high-dose chemotherapy. Cancer 2003;98:406-412. [12872363]
41. Isitt J, Murphy B, Beaumont JL, et al. Oral mucositis (OM) related morbidity and resource utilization is a prospective study of head and neck cancer (HNC) patients. J Clin Oncol 2006;24(18S):5539.
42. Chua KS, Reddy SK, Lee MC, Patt RB. Pain and loss of function in head and neck cancer survivors. J Pain Symptom Manage 11999;18:193-202. [10517041]
43. Weissman DE, Janjan N, Byhardt RW. Assessment of pain during head and neck irradiation. J Pain Symptom Manage 1989;4:90-95. [2732527]
44. Lin A, Jabbari S, Worden FP, et al. Metabolic abnormalities associated with weight loss during chemoirradiation of head and neck cancer. Int J Radiat Oncol Biol Phys 2005;63:1413-1418. [16109461]
45. Murphy BA, Lewin JS, Ridner S, Trotti A. Mechanisms of weight loss in patients with head and neck cancer who were treated with chemoradiation. American Society of Clinical Oncology 2006 Educational Book. Alexandria, Va: American Society of Clinical Oncology;2006:340-344.
46. Silver HJ, Dietrich MS, Murphy BA. Loss of lean body mass and associated physical function decline in the context of increased energy expenditure and inflammatory state in head and neck cancer patients undergoing concurrent chemo-radiation therapy. Head Neck 2007. Epub ahead of print.
47. Murphy BA, Chen A, Harari P, et al. Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN): a new national cancer registry. Proceedings from the 2007 Multidisciplinary Head and Neck Cancer Symposium. January 18-20, 2007. Rancho Mirage, California. Presentation #7.
48. Costa SF, Miceli MH, Anaissie EJ. Mucosa or skin as a source of coagulase-negative staphylococcal bacteraemia? Lancet Infect Dis 2004;4:278-286. [15120344]
49. Elting LS, Cooksley CD, Chambers MS, Garden AS. Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J Radiat Oncol Biol Phys 2007;68:1110-1120. [17398022]
50. Ruescher TJ, Sodeifi A, Scrivani SJ, Kaban LB, Sonis ST. The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer, 1998;82:2275-2281. [9610710]
51. Fanning SR, Rybicki L, Kalaycio M, et al. Severe mucositis is associated with reduced survival after autologous stem cell transplantation for lymphoid malignancies. Br J Haematol 2006;135:374-381. [16995885]
52. Hickok JT, Morrow GR, Roscoe JA, Mustian K, Okunieff P. Occurrence, severity, and longitudinal course of twelve common symptoms in 1129 consecutive patients during radiotherapy for cancer. J Pain Symptom Manage 2005;30:433-442. [16310617]
53. Dantzer R, Kelley KW. Twenty years of research in cytokine-induced sickness behavior. Brain Behav Immun 2007;21:153-160. [17088043]
54. Gutstein HB. The biologic basis of fatigue. Cancer 2001;92(6 suppl):1678-1683. [11598886]
55. Kurzrock R. The role of cytokines in cancer related fatigue. Cancer 2001;92:1684-1688. [11598887]
56. Tisdale MJ. Metabolic abnormalities in cachexia and anorexia. Nutrition 2000;16:1013-1014. [11054609]
57. Tisdale MJ. Biology of cachexia. J Natl Cancer Inst 1997;89:1763-1773. [9392617]
58. Berzon R. Understanding and using health-related quality of life instruments within clinical research studies. In: Quality of Life Assessment in Clinical Trials: Methods and Practice. Staquet MJ, Hays RD, Fayers PM, eds. Oxford: Oxford University Press; 2000; 3-15.
59. Osoba D. Guidelines for measuring health-related quality of life clinical trials. In: Quality of Life Assessment in Clinical Trials: Methods and Practice. Staquet MJ, Hays RD, Fayers PM, eds. Oxford: Oxford University Press; 2000; 19-35.
60. Murphy BA, Ridner S, Wells N, Dietrich M. Quality of life research in head and neck cancer: a review of the current state of the science. Crit Rev Oncol Hematol 2007;62:251-267. [17408963]
61. Peterman A, Celia D, Glandon G, Dobrez D, Yount S. Mucositis in head and neck cancer: economic and quality-of-life outcomes. J Natl Cancer Inst Monogr 2001;29:45-51. [11694566]
62. Epstein JB, Emerton S, Kolbinson DA. Quality of life and oral function following radiotherapy for head and neck cancer. Head Neck 1999;21:1-11. [9890345]
63. Elting LS, Cooksley C, Garden AS. Clinical outcomes of radiotherapy-induced oral mucositis among patients with head and neck cancers. Proceedings from the 17th MASCC/ISOO International Symposium. Geneva, Switzerland. June 30-July 2,2005. Abstract #15-096.